Drugs / PORUSTOBART
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05167071 | Dec 2021 → Sep 2025 overdue | cancer, neuroendocrine neoplasm | Harbour BioMed (Guangzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05149027 | Dec 2021 → May 2024 | cancer | Harbour BioMed (Guangzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04866485 | Jun 2021 → Feb 2023 | neoplasm | Harbour BioMed (Guangzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04727164 | Feb 2021 → Nov 2023 | cancer | Harbour BioMed (Guangzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04135261 | Sep 2019 → Jan 2023 | neoplasm | Harbour BioMed US, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PORUSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095342 ↗ |
| Known as | HBM4003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135261 ↗ |
| Action | Deplete | “designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity” PMID 39366752 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “a novel fully human anti-CTLA-4 monoclonal antibody” PMID 40521168 ↗ Jun 2025 |
| Route | Intravenous | “Intravenous (IV) administration” NCT04135261 ↗ |
| Target | CTLA4 | “anti-CTLA-4” PMID 39366752 ↗ Oct 2024 |